Sunitinib (Sutent)

An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.

Also Known As:

Networked: 4210 relevant articles (652 outcomes, 1094 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Motzer, Robert J: 101 articles (10/2022 - 01/2006)
2.	Rini, Brian I: 89 articles (10/2022 - 12/2005)
3.	Choueiri, Toni K: 67 articles (10/2022 - 01/2008)
4.	Escudier, Bernard: 63 articles (02/2022 - 01/2008)
5.	Powles, Thomas: 57 articles (10/2022 - 09/2008)
6.	Porta, Camillo: 51 articles (07/2022 - 08/2008)
7.	Ravaud, Alain: 47 articles (10/2021 - 01/2008)
8.	Raymond, Eric: 34 articles (01/2021 - 01/2006)
9.	Atkins, Michael B: 32 articles (10/2022 - 09/2008)
10.	Oudard, Stéphane: 30 articles (01/2022 - 01/2007)

Related Diseases

1.	Renal Cell Carcinoma (Grawitz Tumor) 09/01/2020 - "Complete remission of metastatic renal cell carcinoma to the bone with sunitinib." 05/01/2017 - "Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)." 04/01/2015 - "Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy." 12/01/2014 - "We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. " 09/01/2011 - "We report a case with a complete pathology-proven remission after sunitinib treatment of a relapsed irresectable clear cell renal carcinoma. "
2.	Neoplasms (Cancer) 10/01/2020 - "Compared to single-agent sunitinib treatment, tumors in sunitinib-treated ΕC-βKO mice showed a marked decrease in microvessel density, and reduced new vessel formation. " 05/01/2015 - "In vivo, administration of sunitinib induced the significantly marked growth inhibition of PC3/sh-Akt1 compared with that of PC3/C, and apoptotic index in PC3/sh-Akt1 tumor in mice treated with sunitinib was significantly greater than that in PC3/C tumor. " 08/01/2009 - "Sunitinib has proven efficacy in the management of metastatic RCC (mRCC), however, there is very limited evidence of primary tumor response. " 05/01/2006 - "Thus, the potent efficacy of SU11248 in models representing diverse signaling paradigms results from simultaneous inhibition of individual target receptors expressed both in cancer cells and in the tumor neovasculature, supporting the hypothesis that multitargeted inhibitors have the cumulative antitumor efficacy of combined single-target inhibitors." 10/01/2020 - "The results indicate that RFA induced tumor destruction and release of in situ TSAs which can activate a tumoricidal immune response in sunitinib-treated mice, significantly improving anti-HCC therapeutic efficacy. "
3.	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 11/15/2019 - "Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine." 06/01/2013 - "Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience." 01/01/2019 - "Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial." 01/01/2018 - "This study aimed to identify single-nucleotide polymorphisms (SNPs) that are associated with outcome to treatment with sunitinib in patients with advanced gastrointestinal stromal tumors (GIST). " 01/15/2016 - "Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial."
4.	Neoplasm Metastasis (Metastasis) 05/01/2017 - "In this report, we describe a 48-year-old woman with unresectable multiple liver metastases and a colonic metastasis of RCC who was treated with sunitinib in combination with hepatic microwave ablation and obtained a clinical and pathological complete remission. " 12/01/2009 - "Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases." 01/01/2018 - "Here, we describe a case of a single pituitary metastasis from clear cell RCC in a patient who showed a surprising progression-free survival and overall survival to sunitinib first-line treatment. " 01/01/2016 - "Withdrawal of sunitinib led to progression of disease, and resuming use of sunitinib was still effective for multiple lung metastases. " 12/01/2010 - "Results suggest targeted agents such as sunitinib may be an effective treatment for bone metastases."
5.	Kidney Neoplasms (Kidney Cancer) 01/01/2010 - "The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer." 11/01/2015 - "Kidney cancer: Sunitinib: 2/1 is superior to 4/2." 09/01/2008 - "Sunitinib is widely used as first-line treatment for metastatic clear cell renal cancer (MCRC). " 12/14/2012 - "The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic renal cancer." 04/12/2018 - "Key eligibility criteria are the following: patients with locally advanced inoperable or MRCC who are starting first-line treatment with sunitinib, with histologically or cytologically confirmed renal cancer clear cell variant or with a clear cell component, and with Karnofsky performance status ≥70%. "

Related Drugs and Biologics

1.	Sorafenib (BAY 43-9006)
2.	Tyrosine Kinase Inhibitors
3.	pazopanib
4.	Imatinib Mesylate (Gleevec)
5.	Bevacizumab (Avastin)
6.	Everolimus
7.	Nivolumab
8.	Axitinib (AG 013736)
9.	pembrolizumab
10.	cabozantinib

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Nephrectomy
4.	Aftercare (After-Treatment)
5.	Neoadjuvant Therapy